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Introduction
Modern pharmaceutical industry in India emerged in the
1900s and with that regulation of pharmaceuticals also
evolved. The reforms of the 90s while improving the
exports, also brought in improved standards of quality to
be followed in the entire supply chain of drugs. While for
the manufacturers it meant documentation, increased
expenditure, and more export opportunities, for the con-
sumer it has resulted in improved drugs, as the public
health system also started emphasizing on selecting only
those manufacturers with quality standards. However, gov-
ernance and enforcement mechanisms have to improve to
benefit the consumers and the entire healthcare system.
Methods
Based on a review of literature on pharmaceutical regula-
tions governing manufacturing standards, pharmacy edu-
cation, and drug prices, this paper discusses the positive
outcome of certain regulations and points out where expli-
cit policy focus is needed. Specifically, the paper discusses
(a) the positive outcomes of implementing good manufac-
turing practices (GMP) that has improved the standards of
production; (b) the need for aggressive pharmacovigilence
practices to enhance awareness on adverse drug reaction;
(c) the need to integrate the pharmacy education with the
needs of the health systems which functions with far mini-
mal trained human resources particularly in the preventive
health care; and (d) the impact of issues related to the
drug price control orders on the consumers.
Results and discussion
Modern pharmaceutical industry in India emerged in the
1900s. Regulation of pharmaceuticals also emerged with
the industry. The ultimatum given to the industry to
adhere to the schedule M implementation has resulted in
improving the standards of medicines produced. While
the industry-centric regulations emphasize on quality, little
attention is paid particularly to the pharmacovigilence
practices to systematically document the adverse drug
reactions. The pharmacy education in India has an indus-
try bias. Every year, because of the spate of permissions for
pharmacy colleges from the All India Council of Technical
Education, pharmacists are churned out in thousands in
the country. However, they do not find jobs in the indus-
try. If the pharmacy education is oriented towards com-
munity pharmacy or hospital pharmacy, the human
resources shortfall in the preventive health care could be
improved.
The Drug Price Control Order presently covers only 75
essential drugs and leaves out the new innovator drugs
and the biotechnology based drugs, which are prohibitively
expensive. While manufacturers wriggle out of price con-
trol by producing combinations so that they do not come
under the purview of price control, consumers are inun-
dated with irrational an combination that push up the cost
of treatment but delays the course of treatment.
The Drugs and Cosmetics Act needs to be revamped
taking into consideration the changing industrial scenario.
While manufacturers wriggle out of price control by pro-
ducing combinations so that they do not come under the
purview of price control, consumers are inundated with
irrational combinations that push up the cost of treatment
but delay the course of treatment. Pharmaceutical govern-
ance can be vastly improved if the regulatory authorities
have more manpower with them.
In India generic drugs are sold in brand names, which
push up the cost of treatment as doctors prescribe
branded generics. Instead if drugs are sold in generic
names, the cost could be contained. The bureaucratic
bottlenecks particularly at the state level that delays the
spread of Jan-Aushadhi stores need to be addressed.
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The curriculum of pharmacy education should be
revised thoroughly. Pharmacy education in India should
include courses like community/hospital pharmacy,
where the pharmacist actually assists the doctor in
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